Literature DB >> 32184947

Spotlight on AKT: Current Therapeutic Challenges.

Ina Landel1, Lena Quambusch1, Laura Depta1, Daniel Rauh1.   

Abstract

The protein kinase B (Akt) exemplifies an important switch of cell death and survival within the PI3K/Akt signaling pathway, which renders Akt a valuable target in diseases such as cancer. Herein, we give a short overview of clinical applications involving Akt, outline promising and innovative approaches to investigate the role of this kinase in diseases, and highlight the current challenges that require thorough investigation to set the groundwork for successful therapeutic strategies.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID： 32184947      PMCID： PMC7073864          DOI： 10.1021/acsmedchemlett.9b00548

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  15 in total

1.  AKT Inhibition in Solid Tumors With AKT1 Mutations.

Authors:  David M Hyman; Lillian M Smyth; Mark T A Donoghue; Shannon N Westin; Philippe L Bedard; Emma J Dean; Hideaki Bando; Anthony B El-Khoueiry; José A Pérez-Fidalgo; Alain Mita; Jan H M Schellens; Matthew T Chang; Jonathan B Reichel; Nancy Bouvier; S Duygu Selcuklu; Tara E Soumerai; Jean Torrisi; Joseph P Erinjeri; Helen Ambrose; J Carl Barrett; Brian Dougherty; Andrew Foxley; Justin P O Lindemann; Robert McEwen; Martin Pass; Gaia Schiavon; Michael F Berger; Sarat Chandarlapaty; David B Solit; Udai Banerji; José Baselga; Barry S Taylor
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

Review 2.  AKT in cancer: new molecular insights and advances in drug development.

Authors:  Prabhjot S Mundi; Jasgit Sachdev; Carolyn McCourt; Kevin Kalinsky
Journal:  Br J Clin Pharmacol       Date:  2016-06-27       Impact factor: 4.335

3.  First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.

Authors:  Chiara Leoni; Giuseppe Gullo; Nicoletta Resta; Anna Fagotti; Roberta Onesimo; Brian Schwartz; Julia Kazakin; Giovanni Abbadessa; John Crown; Conor D Collins; Carlotta Ranieri; Giovanni Scambia; Giuseppe Zampino
Journal:  Am J Med Genet A       Date:  2019-05-06       Impact factor: 2.802

Review 4.  Circumventing cancer drug resistance in the era of personalized medicine.

Authors:  Levi A Garraway; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

Review 5.  Akt signalling in health and disease.

Authors:  Ingeborg Hers; Emma E Vincent; Jeremy M Tavaré
Journal:  Cell Signal       Date:  2011-05-17       Impact factor: 4.315

6.  A kinase-independent function of AKT promotes cancer cell survival.

Authors:  Igor Vivanco; Zhi C Chen; Barbara Tanos; Barbara Oldrini; Wan-Ying Hsieh; Nicolas Yannuzzi; Carl Campos; Ingo K Mellinghoff
Journal:  Elife       Date:  2014-12-31       Impact factor: 8.140

7.  Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

Authors:  Yi Yu; Ronald E Savage; Sudharshan Eathiraj; Justin Meade; Michael J Wick; Terence Hall; Giovanni Abbadessa; Brian Schwartz
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 8.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

9.  Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.

Authors:  Yan Xing; Nancy U Lin; Matthew A Maurer; Huiqin Chen; Armeen Mahvash; Aysegul Sahin; Argun Akcakanat; Yisheng Li; Vandana Abramson; Jennifer Litton; Mariana Chavez-MacGregor; Vicente Valero; Sarina A Piha-Paul; David Hong; Kim-Anh Do; Emily Tarco; Dianna Riall; Agda Karina Eterovic; Gerburg M Wulf; Lewis C Cantley; Gordon B Mills; L Austin Doyle; Eric Winer; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  Breast Cancer Res       Date:  2019-07-05       Impact factor: 6.466

10.  Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity.

Authors:  Lena Quambusch; Ina Landel; Laura Depta; Jörn Weisner; Niklas Uhlenbrock; Matthias P Müller; Franziska Glanemann; Kristina Althoff; Jens T Siveke; Daniel Rauh
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-08       Impact factor: 15.336
View more
  8 in total

1.  AKT Isoforms as a Target in Cancer and Immunotherapy.

Authors:  Daniel J Smit; Manfred Jücker
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

2.  Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.

Authors:  Xufen Yu; Jia Xu; Yudao Shen; Kaitlyn M Cahuzac; Kwang-Su Park; Brandon Dale; Jing Liu; Ramon E Parsons; Jian Jin
Journal:  J Med Chem       Date:  2022-02-04       Impact factor: 7.446

Review 3.  Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.

Authors:  Mariam Mroweh; Gaël Roth; Thomas Decaens; Patrice N Marche; Hervé Lerat; Zuzana Macek Jílková
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

Review 4.  PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.

Authors:  Shuo Deng; Hin Chong Leong; Arpita Datta; Vennila Gopal; Alan Prem Kumar; Celestial T Yap
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

5.  Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.

Authors:  Dazhi Liu; Michael A Weintraub; Christine Garcia; Marcus D Goncalves; Ann Elizabeth Sisk; Alissa Casas; James J Harding; Stephen Harnicar; Alexander Drilon; Komal Jhaveri; James H Flory
Journal:  Cancer Med       Date:  2022-02-25       Impact factor: 4.711

6.  UBE2T promotes β-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation.

Authors:  Elisavet Lioulia; Panagiotis Mokos; Emmanuel Panteris; Dimitra Dafou
Journal:  Mol Oncol       Date:  2022-03-16       Impact factor: 7.449

7.  Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach.

Authors:  Leandi van der Westhuizen; Jörn Weisner; Abu Taher; Ina Landel; Lena Quambusch; Marius Lindemann; Niklas Uhlenbrock; Matthias P Müller; Ivan R Green; Stephen C Pelly; Daniel Rauh; Willem A L van Otterlo
Journal:  ChemMedChem       Date:  2022-03-09       Impact factor: 3.540

8.  Novel mechanism of napabucasin, a naturally derived furanonaphthoquinone: apoptosis and autophagy induction in lung cancer cells through direct targeting on Akt/mTOR proteins.

Authors:  Korrakod Petsri; Sunisa Thongsom; Satapat Racha; Supakarn Chamni; Saresa Jindapol; Nantawat Kaekratoke; Hongbin Zou; Pithi Chanvorachote
Journal:  BMC Complement Med Ther       Date:  2022-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.